These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6882879)

  • 41. Disopyramide pharmacokinetics in the elderly after single oral administration.
    Roberto P; Vitaliano B; Donatella P; Raffaella M; Sergio B; Gabriella C
    Pharmacol Res Commun; 1988 Dec; 20(12):1025-34. PubMed ID: 3211990
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A simple method for the simulation of unbound serum disopyramide concentration in patients.
    Kishino S; Kohri N; Iseki K; Miyazaki K; Nomura A; Yasuda H
    J Pharmacobiodyn; 1991 Sep; 14(9):493-9. PubMed ID: 1779403
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Disopyramide kinetics in renal impairment: determinants of interindividual variability.
    Burk M; Peters U
    Clin Pharmacol Ther; 1983 Sep; 34(3):331-40. PubMed ID: 6883909
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bioavailability of disopyramide in normal volunteers using unbound concentration.
    Braun J; Sörgel F; Gluth WP; Oie S
    Eur J Clin Pharmacol; 1987; 32(6):625-9. PubMed ID: 3653232
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Disopyramide binding to serum protein in man and animals.
    Lima JJ; Haughey DB
    Drug Metab Dispos; 1981; 9(6):582-3. PubMed ID: 6120822
    [No Abstract]   [Full Text] [Related]  

  • 46. Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment.
    Johnston A; Henry JA; Warrington SJ; Hamer NA
    Br J Clin Pharmacol; 1980 Sep; 10(3):245-8. PubMed ID: 7437241
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Disopyramide kinetics in patients with acute myocardial infarction.
    Ilett KF; Madsen BW; Woods JD
    Clin Pharmacol Ther; 1979 Jul; 26(1):1-7. PubMed ID: 445953
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics of disopyramide in patients with chronic renal failure.
    Francois B; Mallein R; Rondelet J; Lussignol M
    Eur J Drug Metab Pharmacokinet; 1983; 8(1):85-92. PubMed ID: 6861798
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pharmacokinetic and metabolic study of disopyramide in oral and intravenous administration].
    De Graeve J; Kremers P; Gielen JE
    Therapie; 1977; 32(2):195-204. PubMed ID: 898127
    [No Abstract]   [Full Text] [Related]  

  • 50. Pharmacokinetics of disopyramide administered by intramuscular, intravenous and oral routes to normal volunteers [proceedings].
    Ashford JJ; Carmichael D; Kidner PH
    Br J Pharmacol; 1979 Jul; 66(3):442P-443P. PubMed ID: 526732
    [No Abstract]   [Full Text] [Related]  

  • 51. Protein binding of disopyramide--displacement by mono-N-dealkyldisopyramide and variation with source of alpha-1-acid glycoprotein.
    Haughey DB; Steinberg I; Lee MH
    J Pharm Pharmacol; 1985 Apr; 37(4):285-8. PubMed ID: 2860235
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Frequency and voltage-dependent effects of mono-N-dealkyldisopyramide, the major metabolite of disopyramide, in canine ventricular tissue.
    Toy W; Sasyniuk BI
    J Pharmacol Exp Ther; 1990 Aug; 254(2):603-11. PubMed ID: 2166798
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Elimination kinetics and urinary excretion of disopyramide in human healthy volunteers.
    Bonde J; Jensen NM; Pedersen LE; Graudal NA; Angelo HR; Kampmann JP
    Pharmacol Toxicol; 1988 May; 62(5):298-301. PubMed ID: 3413032
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The renal clearance of disopyramide after bolus intravenous injection.
    Lawrence JR; Bryson SM; Sumner DJ; Campbell BC; Whiting B
    Biopharm Drug Dispos; 1979; 1(2):51-7. PubMed ID: 552861
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the effects of cimetidine and ranitidine on the pharmacokinetics of disopyramide in man.
    Jou MJ; Huang SC; Kiang FM; Lai MY; Chao PD
    J Pharm Pharmacol; 1997 Nov; 49(11):1072-5. PubMed ID: 9401940
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Disopyramide pharmacokinetics and metabolism: effect of inducers.
    Kapil RP; Axelson JE; Mansfield IL; Edwards DJ; McErlane B; Mason MA; Lalka D; Kerr CR
    Br J Clin Pharmacol; 1987 Dec; 24(6):781-91. PubMed ID: 3440098
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients.
    Haughey DB; Kraft CJ; Matzke GR; Keane WF; Halstenson CE
    Am J Nephrol; 1985; 5(1):35-9. PubMed ID: 3881959
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Binding interaction between enantiomers of disopyramide and mono-N-dealkyldisopyramide on plasma protein.
    Takahashi H; Ogata H; Seki Y
    Drug Metab Dispos; 1991; 19(2):554-7. PubMed ID: 1676669
    [No Abstract]   [Full Text] [Related]  

  • 59. The pharmacokinetics of disopyramide in patients with acute myocardial infarction.
    Jounela AJ; Pentikäinen PJ; Oksanen K
    Int J Clin Pharmacol Ther Toxicol; 1982 Jun; 20(6):276-82. PubMed ID: 7107076
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disopyramide hemodialysis and kinetics in patients requiring long-term hemodialysis.
    Sevka MJ; Matthews SJ; Nightingale CH; Izard MW; Fieldman A; Chow MS
    Clin Pharmacol Ther; 1981 Mar; 29(3):322-6. PubMed ID: 7471602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.